Olli Silvennoinen

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 11

Top Topics

Acute Myeloid Leukemia

Molecular Docking

Binding Protein

Top Venues

Science advances

Pharmaceuticals (Basel, Switzerland)

FASEB bioAdvances

Nature chemical biology

This page only lists publications with an associated author ORCID identifier.

Publications

Bobin George Abraham, Teemu Haikarainen, Joni Vuorio, Mykhailo Girych, Anniina T Virtanen, Antti Kurttila, Christos Karathanasis, Mike Heilemann, Vivek Sharma, Ilpo Vattulainen, Olli Silvennoinen
Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling. Science advances 10 (10) (2024)
Bobin George Abraham, Teemu Haikarainen, Joni Vuorio, Mykhailo Girych, Anniina T Virtanen, Antti Kurttila, Christos Karathanasis, Mike Heilemann, Vivek Sharma, Ilpo Vattulainen, Olli Silvennoinen
Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling. Science advances 10 (10) (2024)
Bobin George Abraham, Teemu Haikarainen, Joni Vuorio, Mykhailo Girych, Anniina T Virtanen, Antti Kurttila, Christos Karathanasis, Mike Heilemann, Vivek Sharma, Ilpo Vattulainen, Olli Silvennoinen
Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling. Science advances 10 (10) (2024)
Bobin George Abraham, Teemu Haikarainen, Joni Vuorio, Mykhailo Girych, Anniina T Virtanen, Antti Kurttila, Christos Karathanasis, Mike Heilemann, Vivek Sharma, Ilpo Vattulainen, Olli Silvennoinen
Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling. Science advances 10 (10) (2024)
Anniina T Virtanen, Teemu Haikarainen, Parthasarathy Sampathkumar, Maaria Palmroth, Sanna Liukkonen, Jianping Liu, Natalia Nekhotiaeva, Stevan R Hubbard, Olli Silvennoinen
Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)
Anniina T Virtanen, Teemu Haikarainen, Parthasarathy Sampathkumar, Maaria Palmroth, Sanna Liukkonen, Jianping Liu, Natalia Nekhotiaeva, Stevan R Hubbard, Olli Silvennoinen
Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)
Anniina T Virtanen, Teemu Haikarainen, Parthasarathy Sampathkumar, Maaria Palmroth, Sanna Liukkonen, Jianping Liu, Natalia Nekhotiaeva, Stevan R Hubbard, Olli Silvennoinen
Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)
Anniina T Virtanen, Teemu Haikarainen, Parthasarathy Sampathkumar, Maaria Palmroth, Sanna Liukkonen, Jianping Liu, Natalia Nekhotiaeva, Stevan R Hubbard, Olli Silvennoinen
Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)
Juha Saarikettu, Saara Lehmusvaara, Marko Pesu, Ilkka Junttila, Juha Partanen, Petra Sipilä, Matti Poutanen, Jie Yang, Teemu Haikarainen, Olli Silvennoinen
The RNA-binding protein Snd1/Tudor-SN regulates hypoxia-responsive gene expression. FASEB bioAdvances 5 (5) (2023)
Juha Saarikettu, Saara Lehmusvaara, Marko Pesu, Ilkka Junttila, Juha Partanen, Petra Sipilä, Matti Poutanen, Jie Yang, Teemu Haikarainen, Olli Silvennoinen
The RNA-binding protein Snd1/Tudor-SN regulates hypoxia-responsive gene expression. FASEB bioAdvances 5 (5) (2023)
Olli Silvennoinen, Teemu Haikarainen, Anniina Virtanen
Aiming for the pocket. Nature chemical biology 18 (12) (2022)